Sign inJoin waitlistJoin the waitlist

Margaret Lamb

Program Director · Nationwide Children's Hospital

Credentials: · ·

History

Nationwide Children's Hospital
Present

Pediatric Hematology/Oncology
Nationwide Children's Hospital
2016–2019
Pediatrics
Nationwide Children's Hospital
2013–2016
Ohio State University College of Medicine
2009–2013

Research

COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients
Systematic review or meta-analysis · Journal of Infection · 2021 · 187 citations
Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
Review · Stem Cell Research & Therapy · 2021 · First of 4 authors · Corresponding · 66 citations
Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins
Journal of Visualized Experiments · 2018 · 57 citations

Dean Lee
10 papers
GB
Gregory Behbehani
3 papers
Adam Kittai
2 papers
Brian Tullius
2 papers
EB
Evandro Bezerra
2 papers
Hemalatha Rangarajan
2 papers
IS
Ivana Stojkic
2 papers · 2 as a fellow
Jeffery Auletta
2 papers
Jennifer Aldrink
2 papers
Jennifer Woyach
2 papers
KL
Karilyn Larkin
2 papers
KR
Kerry Rogers
2 papers

Clinical trials

Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML
Principal investigator · Not yet recruiting · Phase 1, Phase 2
Nationwide Children's Hospital
2026–2038
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Principal investigator · Not yet recruiting · Early phase 1
Nationwide Children's Hospital
2025–2035
Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
Principal investigator · Recruiting · Phase 1, Phase 2
Nationwide Children's Hospital
2022–2027
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Site PI · Recruiting · Phase 1
Sumithira Vasu
2022–2027